ArticleScientific reports2018
Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 82 citations in OpenAlex.
- Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes.Acta pharmaceutica Sinica. B · 2026Review
- Oral Treatment of Obesity by GLP-1 and Its Analogs.Pharmaceutics · 2025Review
- Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.Nutrition & diabetes · 2025Review
- Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.Pharmaceutics · 2025Review
- Biodegradable Conducting Polymer-Based Composites for Biomedical Applications-A Review.Polymers · 2024Review
- Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives.Acta pharmaceutica Sinica. B · 2024Review
- A Comparative Study on Improving Streptozotocin-Induced Type 2 Diabetes in Rats by Hydrosol, Extract and Nanoemulsion Prepared from Cinnamon Leaves.Antioxidants (Basel, Switzerland) · 2022Article
- Recent Advances in Biodegradable Polymers and Their Biological Applications: A Brief Review.Polymers · 2022Review
- Efficient aqueous remote loading of peptides in poly(lactic-co-glycolic acid).Nature communications · 2022Article
- Nanobiotechnology with Therapeutically Relevant Macromolecules from Animal Venoms: Venoms, Toxins, and Antimicrobial Peptides.Pharmaceutics · 2022Review
- Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.Acta pharmaceutica Sinica. B · 2022Review
- Molecular prospect of type-2 diabetes: Nanotechnology based diagnostics and therapeutic intervention.Reviews in endocrine & metabolic disorders · 2021Review
- The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Article
- Oral Delivery of Biologics via the Intestine.Pharmaceutics · 2020Review
- Nanoparticle modification in biological media: implications for oral nanomedicines.RSC advances · 2019Review
- Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide.Pharmaceutics · 2019Article
- Nanomagnetite-embedded PLGA Spheres for Multipurpose Medical Applications.Materials (Basel, Switzerland) · 2019Article
- Delivery of Nanoparticles across the Intestinal Epithelium via the Transferrin Transport Pathway.Pharmaceutics · 2019Article
- Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery.Computational and structural biotechnology journal · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To improve the oral efficiency of exenatide, we prepared polyethylene glycol-poly(lactic-co-glycolic acid) (PEG-PLGA) NPs modified with Fc (NPs-Fc) for exenatide oral delivery. Exenatide was encapsulated into the NPs by the w/o/w emulsion-solvent evaporation method. The particle size of the NPs-Fc was approximately 30 nm larger than that of the unmodified NPs with polydispersity indices in a narrow range (PDIs; PDI < 0.3) as detected by DLS, and the highest encapsulation efficiency of exenatide in the NPs was greater than 80%. Fc-conjugated NPs permeated Caco-2 cells faster and to a greater extent compared to unmodified NPs, as verified by CLSM and flow cytometry. Hypoglycemic effect studies demonstrated that oral administration of exenatide-loaded PEG-PLGA NPs modified by an Fc group extended the hypoglycemic effects compared with s.c. injection of the exenatide solution. Fluorescence-labeled NPs were used to investigate the effects of Fc targeting, and the results demonstrated that the NPs-Fc stayed in the gastrointestinal tract for a longer time in comparison with the unmodified NPs, as shown by the whole-body fluorescence images and fluorescence images of the dissected organs detected by in vivo imaging in live mice. Therefore, Fc-targeted nano-delivery systems show great promise for oral peptide/protein drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.